15Oct
08Oct
With Datacastle acquisition, cloud storage company Carbonite looks to grow in Seattle
Carbonite became one of Seattle’s latest arrivals with its acquisition of Datacastle earlier this year, and it’s evaluating expansion plans as it eyes the amount of cloud computing talent in the region. Read more >>
06Oct
What is eSight Eyewear and How Can It Help?
Jill Barkley speaks to Jeff Fenton, director of outreach and communications for eSight, about the new technology that enables partially sighted people to see, and independently work and study. Read more >>
06Oct
St. Peter’s student fulfills visual wish with eSight glasses
Remington Hedrick, a second grader at St. Peter's Elementary School, can see her classmates' faces for the first time thanks to a new pair of eSight glasses.
05Oct
YouTube shows 65% growth for beauty and personal care vids, Pixability study reveals
In its 4th annual beauty study, video advertising technology company, Pixability, reveals its latest beauty space social insights and adds personal care video ecosystems findings to its report. Read more >>
05Oct
Siamab Therapeutics and Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration to Develop Antibody Therapeutics Targeting Multiple Solid Tumors
Siamab Therapeutics, Inc. and Boehringer Ingelheim announced today that they have entered into a strategic discovery collaboration with the goal of developing anti-cancer therapeutics targeting tumor associated carbohydrate antigens (TACAs). Read more >>
04Oct
New technology helps the blind to see
It's helping the blind to see. A couple in the northern valley was worried that it was an out-of-country scam, but now they want to share what's bringing back a man's sight. Read more >>
04Oct
ESight launches next generation eye wear for visually impaired
The eye wear technology company, eSight, has launched the third generation of its hands-free glasses that provide instant sight and mobility for those with impaired vision. Read more >>
04Oct
Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) that show inhibition of tumor progression in in vivo and in vitro patient derived xenograft (PDX) ovarian cancer models with complete regression in some treatment arms. Read more >>
01Oct